All issues > Volume 36(1); 1993

Original Article

J Korean Pediatr Soc. 1993;36(1):9-16. Published online January 15, 1993.

Acute Megakaryoblastic Leukemia in Children

Hong Hoe HH Koo¹, Sang Kyu SK Park¹, Eun Sil ES Dong¹, Hye Jung HJ Park¹, Hee Young HY Shin¹, Hyo Seop HS Ahn¹

¹Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea

Abstract

We analyzed the clinical and laboratory features of ten children with acute megakaryoblastic leukemia (M7) and compared the findings with those reported in the literature. The diagnosis was supported by ultrastructural examination of platelet peroxidase or immunophenotyping for glycoprotein Iib/IIIa. Of the ten children, five were girls and five were boys. The median age at diagnosis was 13 months. Two patients had prominent myelofibrosis and one patient had Down syndrome. Nine was 13 months. Two patients had prominent myelofibrosis and one patient had Down syndrome. Nine patients were treated with low-dose cytosine arabinoside (10mg/m2) administered intravenously, or subcutaneously, or intramuscularyly, twice daily in 21 day courses. Seven patients achieved hematologic response and three patients are alive without evidence of disease. The 4 year event free survival rate was 30.0%. It is our impression that the prevalence of acute megakaryoblastic leukemia has been under-estimated, and low-dose cytosine arabinoside treatment may be of value in its management. This approach may be particularily useful in hospitals with scarce well-equipped facilities, since this protocol does not induce profound marrow hypopasia and intensive supportive measures are not required as they would be with the use of more aggressive drug combination.

Keywords :Acute megakaryobastic leukemia, Children, Low-dose Ara-C